Pulmonary Hypertension

For PAH, Bioelectronic Medicine May Open New Therapy Avenues - Pulmonary Hypertension News For PAH, Bioelectronic Medicine May Open New Therapy Avenues - Pulmonary Hypertension News Posted: 13 Dec 2019 12:00 AM PST Bioelectronic medicine is a promising new therapeutic approach to treat pulmonary arterial hypertension (PAH), according to a recent review study. The review, " Pulmonary arterial hypertension: the case for a bioelectronic treatment ," was published in the journal Bioelectronic Medicine . Current treatments for PAH include medications that interfere with different signaling cascades in order to lower blood pressure by inducing the widening and relaxation of blood vessels. Despite treatment advancements in recent years, some of these medications can cause undesirable side effects, including low blood pressure , heart complications, headache , muscle pain ,  indigestion ,  nausea , and ...

Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement - Associated Press Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement - Associated Press Predicting Survival in Patients With Pulmonary Arterial Hypertension - Physician's Weekly Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In D | OARRR - Dove Medical Press Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement - Associated Press Posted: 30 Dec 2019 04:37 AM PST CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 30, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, and Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving th...

Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor Posted: 05 Dec 2019 12:00 AM PST A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension (PAH) who received dual endothelin receptor antagonist (ERA)/phosphodiesterase type 5 inhibitor (PDE5i) therapy. The opinions were published in CHEST . Researchers used MEDLINE to perform a systematic literature review of studies between 2008 and 2018 comprising adult patients with connective tissue disease (CTD)-associated PAH and function class (FC) 2 or 3 idiopathic, heritable, repaired congenital heart defect, or drug- or toxin-induced PAH (the latter was considered one etiologic grouping, IPAH+) who were tre...

Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement - Associated Press Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement - Associated Press Posted: 30 Dec 2019 04:37 AM PST CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 30, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, and Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced they have entered into a collaboration and license agreement to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. This press release features multimedia. View the full r...

Bioelectronic medicine shows potential to treat pulmonary hypertension - PRNewswire Bioelectronic medicine shows potential to treat pulmonary hypertension - PRNewswire Posted: 09 Dec 2019 12:00 AM PST PAH, a disease of the pulmonary vessels that causes heart failure and death, is a form of a broader condition known as pulmonary hypertension or high blood pressure in the vessels of the lungs. PAH is caused by narrowing of the arteries that carry blood from the heart to the lungs for oxygenation and often leads to heart failure and death. Current treatments for PAH include several classes of drugs that target signaling pathways in vascular biology and cardiovascular physiology. They can have severe unwanted side effects, and the treatment does not typically stop the progression of the disease. Bioelectronic medicine is an emerging approach to treat and diagnose disease and injury using device technology to modulate the electrical activit...

Drug-Induced Pulmonary Arterial Hypertension: A More Complicated Prognosis - Pulmonology Advisor Drug-Induced Pulmonary Arterial Hypertension: A More Complicated Prognosis - Pulmonology Advisor Posted: 22 Apr 2019 12:00 AM PDT While methamphetamine use had been implicated in myocardial infarction, cardiac arrhythmias, and ischemic cardiomyopathy, recent reports have indicated that intravenous (IV) methamphetamine also attacks the lung tissue. 1 Data compiled at a Stanford University pulmonology clinic in California reported that 85% of drug-induced pulmonary arterial hypertension (D-PAH) stemmed from methamphetamine use. 1 The prognosis for these patients was substantially worse than for patients with idiopathic PAH; the median 5-year survival for patients with D-PAH was 35%. 1 In patients with a history of IV drug use, HIV and hepatitis C virus (HCV) coinfection can complicate the course of PAH. 2 Individuals with HIV who have a higher...

HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases - Pulmonary Hypertension News HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases - Pulmonary Hypertension News Lethal Lung Disease and Biologics: Is There a Link? - MedPage Today PAH May Be Treated With Antiarrhythmic Tikosyn, Study Suggests - Pulmonary Hypertension News HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases - Pulmonary Hypertension News Posted: 06 Dec 2019 12:00 AM PST Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation's highest-ranking health official said. "We have to think about how our financing system can protect those with serious and rare illnesses. When successful therapies are developed, they can be e...